Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
108.51 USD | -0.87% |
|
-3.12% | -10.90% |
09:08am | Sarepta Therapeutics Closes $600 Million Revolving Credit Facility | MT |
08:30am | Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility | CI |
Capitalization | 10.46B 9.95B 9.39B 8.29B 14.81B 906B 16.44B 112B 41.41B 379B 39.19B 38.41B 1,590B | P/E ratio 2024 * |
40.8x | P/E ratio 2025 * | 10.4x |
---|---|---|---|---|---|
Enterprise value | 9.73B 9.26B 8.74B 7.72B 13.78B 843B 15.3B 104B 38.54B 352B 36.47B 35.74B 1,479B | EV / Sales 2024 * |
5.28x | EV / Sales 2025 * | 2.61x |
Free-Float |
95.63% | Yield 2024 * |
-
| Yield 2025 * | - |
Last Transcript: Sarepta Therapeutics, Inc.
1 day | -0.98% | ||
1 week | -3.14% | ||
Current month | -4.76% | ||
1 month | -8.85% | ||
3 months | -0.73% | ||
6 months | -18.61% | ||
Current year | -10.92% |







Director | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 62 | 2017-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 49 | 2020-12-13 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | 2022-12-30 |
Manager | Title | Age | Since |
---|---|---|---|
M. Wilsey
CHM | Chairman | 72 | 2015-04-15 |
Director/Board Member | 87 | 2010-05-31 | |
Richard Barry
BRD | Director/Board Member | 66 | 2015-06-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 1 M€ | 0.00% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.96% | -3.14% | -12.86% | +37.75% | 10.46B | ||
-0.61% | -1.79% | +10.30% | +99.33% | 119B | ||
+0.31% | -4.89% | -28.76% | +8.30% | 72.16B | ||
-2.13% | -3.83% | +68.23% | +140.90% | 39.41B | ||
-3.23% | +1.47% | +30.48% | -22.78% | 29.44B | ||
+2.55% | +3.57% | +58.70% | +12.76% | 24.06B | ||
+4.61% | +2.46% | +11.97% | -28.40% | 22.32B | ||
-1.76% | +6.71% | +382.25% | +957.14% | 16.09B | ||
-0.15% | -1.74% | +186.30% | +241.57% | 14.07B | ||
+0.94% | +8.59% | -19.89% | -31.61% | 13.26B | ||
Average | -0.07% | -0.33% | +68.67% | +141.50% | 36.01B | |
Weighted average by Cap. | -0.28% | -2.50% | +35.51% | +99.24% |
2024 * | 2025 * | |
---|---|---|
Net sales | 1.84B 1.75B 1.65B 1.46B 2.61B 160B 2.9B 19.69B 7.3B 66.72B 6.9B 6.77B 280B | 3.16B 3.01B 2.84B 2.51B 4.48B 274B 4.97B 33.8B 12.52B 115B 11.85B 11.61B 481B |
Net income | 256M 244M 230M 203M 363M 22.17B 402M 2.74B 1.01B 9.27B 959M 940M 38.92B | 1.12B 1.06B 1B 885M 1.58B 96.67B 1.75B 11.93B 4.42B 40.42B 4.18B 4.1B 170B |
Net Debt | -726M -691M -652M -576M -1.03B -62.92B -1.14B -7.77B -2.88B -26.31B -2.72B -2.67B -110B | -2.2B -2.1B -1.98B -1.75B -3.12B -191B -3.46B -23.55B -8.73B -79.8B -8.26B -8.09B -335B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-14 | 108.30 $ | -1.06% | 320,812 |
25-02-13 | 109.46 $ | -0.32% | 712,626 |
25-02-12 | 109.81 $ | +0.12% | 639,621 |
25-02-11 | 109.68 $ | -2.71% | 654,227 |
25-02-10 | 112.74 $ | +0.82% | 604,097 |
Delayed Quote Nasdaq, February 14, 2025 at 01:05 pm EST
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SRPT Stock